StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
002772.SZ$13.66+1.64%
Fair $13.66+0.0%

002772.SZ

Tianshui Zhongxing Bio-technology Co.,Ltd.

Consumer Defensive / Farm ProductsShenzhen

$13.66

+0.22 (+1.64%)

Fairly Valued+0.0%Fair Value $13.66Fund rank 31/100 · Data gapFallback financials|
SA 46/C
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 32% · confianza 24%

FCF escenarios

weak_data · normalized FCF $249.4M · quality 55.3/100

Data gap 31/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 50/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

46/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 002772.SZLocal privado en este navegador · Tianshui Zhongxing Bio-technology Co.,Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$5.1B

P/E

11.5x

↓

EV/EBITDA

9.3x

↑

ROE

9.5%

↑

Gross Margin

28.6%

↑

Debt/Equity

0.82

↑
52-Week Range$14
$7$20

TradingView lightweight chart

002772.SZ price, volumen y niveles de valoración

Último $13.66Periodo +49.7%
Fair value: $13.66

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+2.1%

FCF CAGR

—

FCF margin

-2.6%

FCF / Net income

-0.17x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $2.10B · net income $335.0M · FCF $-55.6M

2022-FY → 2025-FY

Gross margin

28.6%+3.2% pts

Operating margin

16.8%+3.0% pts

Net margin

16.0%+7.9% pts

FCF margin

-2.6%-15.2% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$2.10B$2.10B$1.94B$1.93B$1.97B
Net Income$335.0M$335.0M$128.0M$159.6M$158.4M
EBITDA$707.5M$707.5M$490.0M$511.9M$524.8M
EPS0.890.890.330.390.40
Gross Margin28.6%28.6%20.8%23.0%25.5%
Operating Margin16.8%16.8%8.3%10.8%13.7%
Net Margin16.0%16.0%6.6%8.3%8.0%
Balance Sheet
Debt/Equity0.820.820.710.610.77
Current Ratio2.472.47———
Cash Flow
Free Cash Flow$-55.6M$-55.6M$249.4M$395.5M$247.8M
Returns
ROE9.5%9.5%3.9%4.6%4.7%
Valuation
P/E11.4811.4821.8120.2520.90
EV/EBITDA9.299.298.108.368.74
P/B1.461.460.840.940.98
Growth & Yield
Revenue Growth8.4%8.4%0.2%-2.0%—
EPS Growth172.6%172.6%-16.5%-2.1%—
Dividend Yield3.3%3.3%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

10.8%

razonable

EPS terminal req.

$1.21

Spread vs growth

161.8%

5Y implied EPS CAGR

10.5%

razonable

EPS terminal req.

$1.47

Spread vs growth

162.1%

10Y implied EPS CAGR

10.2%

razonable

EPS terminal req.

$2.36

Spread vs growth

162.4%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +73.6%

Total return

+73.6%

Start / end P/E

24.5x → 15.3x

EPS bridge

0.33 → 0.89

Residual

-64.8%

EPS growth+172.6%
Multiple rerating-37.5%
Dividend+3.3%
Residual / FX / buybacks / cross-term-64.8%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.